4/A: Ionis Pharmaceuticals Director Michael Yang Reports Stock Unit Transaction

Director Michael Yang reports acquisition of restricted stock units in Ionis Pharmaceuticals, adjusted to comply with director compensation policy.

Summary

• Michael J. Yang, a director of Ionis Pharmaceuticals, reported a transaction involving restricted stock units.
• On July 1, 2024, Yang acquired 4,079 restricted stock units, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants were adjusted downward to ensure the non-employee director's annual equity compensation in 2024 does not exceed $450,000, based on the grant date fair value.
• The restricted stock units vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever is earlier.
• The units will be delivered to Yang on July 15th following the vesting date.
• As of July 1, 2024, 0 shares are vested.
• Following the reported transaction, Yang directly owns 9,870 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating standard corporate governance practices. There are no overtly positive or negative implications.

Future Outlook

The restricted stock units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Director compensation packages, including equity grants, are common across publicly traded pharmaceutical companies.
• The $450,000 limit on annual equity compensation appears to be within a reasonable range for non-employee directors in similarly sized companies.
• Companies like Alnylam Pharmaceuticals (ALNY) and Sarepta Therapeutics (SRPT), which are in a similar space to Ionis, also utilize stock options and restricted stock units as part of their director compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it relates to director compensation and equity dilution.
• The director benefits from the equity grant, aligning their interests with those of the shareholders.

Key Dates